Teladoc Health Future Growth
Future criteria checks 0/6
Teladoc Health is forecast to grow earnings and revenue by 47.7% and 3.2% per annum respectively. EPS is expected to grow by 48.4% per annum. Return on equity is forecast to be -4.6% in 3 years.
Key information
47.7%
Earnings growth rate
48.4%
EPS growth rate
| Healthcare Services earnings growth | 27.4% |
| Revenue growth rate | 3.2% |
| Future return on equity | -4.6% |
| Analyst coverage | Good |
| Last updated | 11 Apr 2024 |
Recent future growth updates
Recent updates
Teladoc: Management Has A Lot To Prove To Gain Investor Confidence
Mar 25Teladoc Health, Inc.'s (NYSE:TDOC) 25% Dip In Price Shows Sentiment Is Matching Revenues
Mar 10
Teladoc Health: Another Bad Quarter, Another Wave Of Capitulation
Feb 21Teladoc Health: Weight Management Rescue
Jan 21Teladoc Health (NYSE:TDOC) Is Carrying A Fair Bit Of Debt
Jan 15When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?
Dec 12Teladoc Q3: Getting Stronger (Rating Upgrade)
Nov 29Teladoc Health, Inc.'s (NYSE:TDOC) Intrinsic Value Is Potentially 78% Above Its Share Price
Nov 22Teladoc Was Obliterated
Oct 25Is Teladoc Health (NYSE:TDOC) A Risky Investment?
Oct 11Teladoc: Broken Growth Story Deteriorates Further (Rating Downgrade)
Oct 02Teladoc Stock: A Hold Amid New Covid Wave
Sep 14Teladoc's Technical Decline Hints At A Buying Opportunity
Aug 28Is There An Opportunity With Teladoc Health, Inc.'s (NYSE:TDOC) 44% Undervaluation?
Aug 18Buy Teladoc: AI Will Likely Spur Healthcare Deflation
Aug 16Teladoc's Future: Virtual Healthcare, AI, And Valuation
Jul 28Teladoc And Microsoft's Expanded Strategic Partnership Is A Powerful AI Combo
Jul 21The Big Trends: New Frontiers in Healthcare
Jul 13
When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?
Jul 10Teladoc Health: Likely To Remain Out Of Favor
Jun 26Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors
Jun 25Here's Why Teladoc Health (NYSE:TDOC) Can Afford Some Debt
May 25Teladoc: BetterHelp Segment Margins Are Key
May 23Are Investors Undervaluing Teladoc Health, Inc. (NYSE:TDOC) By 20%?
May 06Is It Too Late To Consider Buying Teladoc Health, Inc. (NYSE:TDOC)?
Mar 10Teladoc Health Non-GAAP EPS of -$0.23 misses by $0.04, revenue of $637.7M beats by $4.33M
Feb 22Is Teladoc Health (NYSE:TDOC) Using Too Much Debt?
Feb 01Teladoc's Stock Is Showing Signs Of Life
Jan 30Teladoc: Unrealistic Assumptions Required To Buy
Jan 09Teladoc: A Bargain If It Ever Reaches GAAP Profitability
Jan 02An Intrinsic Calculation For Teladoc Health, Inc. (NYSE:TDOC) Suggests It's 45% Undervalued
Dec 23Why did Teladoc Health stock fall today? Continued pressure for telehealth providers
Dec 22Teladoc: Death By A Thousand Paper Cuts
Dec 17What Is Teladoc Health, Inc.'s (NYSE:TDOC) Share Price Doing?
Nov 16Amazon Clinic seen putting pressure on telehealth providers Him & Hers Health, Teladoc
Nov 15Teladoc Health GAAP EPS of -$0.45 beats by $0.12, revenue of $611.4M beats by $2.41M
Oct 26Teladoc Health: Focus On Management Guidance And Takeover Potential
Oct 20Teladoc: Cathie Wood Does It Again
Oct 11Teladoc: The White Flag
Sep 27Teladoc: Yes, Patient Investors Are Rewarded Again - Buy This Pullback
Sep 20We Think Teladoc Health (NYSE:TDOC) Has A Fair Chunk Of Debt
Sep 18An Intrinsic Calculation For Teladoc Health, Inc. (NYSE:TDOC) Suggests It's 30% Undervalued
Aug 29Amazon Out. World Of Teladoc Is Unfolding
Aug 25Teladoc slips as Guggenheim hands first Sell rating
Aug 17At US$37.79, Is It Time To Put Teladoc Health, Inc. (NYSE:TDOC) On Your Watch List?
Aug 11Teladoc: Don't Keep Buying Weak Execution And Disappointment
Aug 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,865 | -76 | 313 | 471 | 11 |
| 12/31/2025 | 2,767 | -120 | 277 | 427 | 25 |
| 12/31/2024 | 2,664 | -174 | 215 | 358 | 25 |
| 12/31/2023 | 2,602 | -220 | 194 | 350 | N/A |
| 9/30/2023 | 2,580 | -4,002 | 112 | 285 | N/A |
| 6/30/2023 | 2,531 | -4,018 | 64 | 243 | N/A |
| 3/31/2023 | 2,471 | -7,054 | 47 | 234 | N/A |
| 12/31/2022 | 2,407 | -13,660 | 17 | 189 | N/A |
| 9/30/2022 | 2,323 | -9,860 | 65 | 207 | N/A |
| 6/30/2022 | 2,234 | -9,871 | 107 | 221 | N/A |
| 3/31/2022 | 2,144 | -6,904 | 99 | 180 | N/A |
| 12/31/2021 | 2,033 | -429 | 130 | 194 | N/A |
| 9/30/2021 | 1,862 | -812 | -54 | -4 | N/A |
| 6/30/2021 | 1,629 | -763 | -92 | -49 | N/A |
| 3/31/2021 | 1,367 | -655 | -102 | -65 | N/A |
| 12/31/2020 | 1,094 | -485 | -80 | -54 | N/A |
| 9/30/2020 | 867 | -110 | 59 | 80 | N/A |
| 6/30/2020 | 716 | -95 | 46 | 61 | N/A |
| 3/31/2020 | 606 | -98 | 19 | 31 | N/A |
| 12/31/2019 | 553 | -99 | 19 | 30 | N/A |
| 9/30/2019 | 520 | -105 | 4 | 14 | N/A |
| 6/30/2019 | 493 | -108 | 2 | 11 | N/A |
| 3/31/2019 | 457 | -103 | -8 | 1 | N/A |
| 12/31/2018 | 418 | -97 | -13 | -5 | N/A |
| 9/30/2018 | 372 | -117 | -22 | -15 | N/A |
| 6/30/2018 | 330 | -125 | -44 | -37 | N/A |
| 3/31/2018 | 280 | -115 | -42 | -36 | N/A |
| 12/31/2017 | 233 | -107 | -40 | -34 | N/A |
| 9/30/2017 | 194 | -77 | N/A | -35 | N/A |
| 6/30/2017 | 157 | -75 | N/A | -38 | N/A |
| 3/31/2017 | 139 | -75 | N/A | -47 | N/A |
| 12/31/2016 | 123 | -74 | N/A | -52 | N/A |
| 9/30/2016 | 108 | -75 | N/A | -57 | N/A |
| 6/30/2016 | 96 | -58 | N/A | -59 | N/A |
| 3/31/2016 | 88 | -61 | N/A | -54 | N/A |
| 12/31/2015 | 77 | -58 | N/A | -47 | N/A |
| 9/30/2015 | 68 | -50 | N/A | -39 | N/A |
| 6/30/2015 | 59 | -42 | N/A | -24 | N/A |
| 3/31/2015 | 51 | -29 | N/A | -19 | N/A |
| 12/31/2014 | 44 | -20 | N/A | -11 | N/A |
| 12/31/2013 | 20 | -10 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TDOC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TDOC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TDOC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TDOC's revenue (3.2% per year) is forecast to grow slower than the US market (8.1% per year).
High Growth Revenue: TDOC's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TDOC is forecast to be unprofitable in 3 years.